LSE - Delayed Quote GBp

Smith & Nephew plc (SN.L)

981.00 +16.60 (+1.72%)
At close: April 26 at 4:38 PM GMT+1
Key Events
Loading Chart for SN.L
DELL
  • Previous Close 964.40
  • Open 965.00
  • Bid 981.40 x --
  • Ask 981.60 x --
  • Day's Range 965.00 - 986.20
  • 52 Week Range 887.00 - 1,316.75
  • Volume 4,286,343
  • Avg. Volume 3,622,896
  • Market Cap (intraday) 8.577B
  • Beta (5Y Monthly) 0.51
  • PE Ratio (TTM) 40.88
  • EPS (TTM) 0.24
  • Earnings Date Feb 27, 2024
  • Forward Dividend & Yield 0.30 (3.09%)
  • Ex-Dividend Date Mar 28, 2024
  • 1y Target Est 12.88

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

www.smith-nephew.com

18,452

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SN.L

Smith & Nephew PLC's Dividend Analysis

Smith & Nephew PLC's Dividend Analysis

Performance Overview: SN.L

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SN.L
6.98%
FTSE 100
5.26%

1-Year Return

SN.L
20.28%
FTSE 100
3.15%

3-Year Return

SN.L
28.28%
FTSE 100
17.31%

5-Year Return

SN.L
24.99%
FTSE 100
9.49%

Compare To: SN.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SN.L

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    8.58B

  • Enterprise Value

    10.80B

  • Trailing P/E

    40.76

  • Forward P/E

    12.47

  • PEG Ratio (5yr expected)

    0.46

  • Price/Sales (ttm)

    1.93

  • Price/Book (mrq)

    2.06

  • Enterprise Value/Revenue

    1.95

  • Enterprise Value/EBITDA

    11.30

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.74%

  • Return on Assets (ttm)

    4.27%

  • Return on Equity (ttm)

    5.02%

  • Revenue (ttm)

    5.55B

  • Net Income Avi to Common (ttm)

    263M

  • Diluted EPS (ttm)

    0.24

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    302M

  • Total Debt/Equity (mrq)

    59.11%

  • Levered Free Cash Flow (ttm)

    211.75M

Research Analysis: SN.L

Analyst Price Targets

10.75 Low
12.88 Average
981.00 Current
15.00
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: SN.L

People Also Watch